Physician profile
Michael John Ford
NPI 1508868860
$8,098.06
in general payments reported to CMS, 2019-2025
36 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $550 · 2021: $1,112 · 2022: $1,222 · 2023: $1,287 · 2024: $1,413 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,447.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $937.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $572.22 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Pfizer INC. | $537.83 | 2019-2025 | |
| Genzyme Corporation | $509.22 | 2020-2025 | |
| Ucb, INC. | $461.85 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $444.84 | 2020-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $392.51 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $337.48 | 2019-2024 | Dupixent |
| Janssen Biotech, INC. | $325.56 | 2019-2025 | Tremfya |
| Amgen INC. | $266.31 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $232.35 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $193.95 | 2023 | Xeomin |
| Mayne Pharma Commercial LLC | $174.25 | 2019-2024 | |
| Incyte Corporation | $162.41 | 2021-2025 | Opzelura |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $146.28 | 2019-2024 | Puraply |
| Galderma Laboratories, L.P. | $132.85 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.33 | 2019-2021 | |
| Kerecis Limited | $82.73 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.86 | 2022-2024 | Spevigo |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Organon LLC | $67.68 | 2024-2025 | Hadlima |
| Almirall LLC | $56.22 | 2025 | Klisyri |
| Merck Sharp & Dohme LLC | $50.04 | 2019 | |
| Biofrontera INC. | $39.87 | 2019-2025 | Ameluz |
| Allergan, INC. | $37.44 | 2021-2022 | |
| Sebela Pharmaceuticals INC. | $34.99 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $34.06 | 2025 | Zoryve |
| Misonix INC | $27.56 | 2021 | |
| Strata Skin Sciences, INC. | $25.94 | 2019-2020 | |
| Stemline Therapeutics INC. | $24.53 | 2022 | |
| Abbott Laboratories | $22.13 | 2021 | |
| Celgene Corporation | $19.72 | 2019 | |
| Convatec INC. | $18.85 | 2023 | |
| Janssen Scientific Affairs, LLC | $18.63 | 2019 | |
| Aclaris Therapeutics, INC. | $17.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.